Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate. Aramchol™ is a first in class, orally active, liver targeted SCD – 1 modulator with a dual mode of action on liver fibrosis, down regulation of steatosis and a direct effect on Hepatic Stellate Cells (HSC’s), the human collagen producing cells. Aramchol™ has shown down regulation of liver steatosis and fibrosis in multiple animal models (see also publication section) demonstrating its effect on the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol™ on NASH pathologies in animals was translated into humans in a phase IIa clinical study and is currently being examined in the Phase IIb ARREST study (see also Clinical Development section). To date, over 400 patients have been exposed to Aramchol™ across 7 clinical trials. No safety and tolerability signals have been identified thus far. Aramchol™ has been granted Fast Track designation status by the FDA for the treatment of NASH.